The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas

被引：0
|
作者：
Zeimet, A. G. [1 ]
Leitner, K. [1 ]
Hackl, H. [2 ]
Fiegl, H. [1 ]
Feroz, B. [1 ]
Marth, C. [1 ]
Steger, K. [1 ]
机构：
[1] Med Univ Innsbruck, Gynecol & Obstet, Innsbruck, Austria
[2] Med Univ Innsbruck, Inst Bioinformat, Innsbruck, Austria
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
792P
引用
收藏
页码：S591 / S591
页数：1
相关论文
共 50 条
  • [1] Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer
    Steger, Katharina
    Fiegl, Heidelinde
    Feroz, Barin
    Leitner, Katharina
    Marth, Christian
    Hackl, Hubert
    Zeimet, Alain G.
    EUROPEAN JOURNAL OF CANCER, 2025, 219
  • [2] Diagnostic and Prognostic Value of TP53 Expression in Ovarian High-Grade Serous Carcinomas
    Kobel, M.
    Reuss, A.
    DuBois, A.
    Kommoss, S.
    Kommoss, F.
    Gao, D.
    Kalloger, S. E.
    Huntsman, D. G.
    Gilks, C. B.
    LABORATORY INVESTIGATION, 2010, 90 : 250A - 250A
  • [3] Diagnostic and Prognostic Value of TP53 Expression in Ovarian High-Grade Serous Carcinomas
    Kobel, M.
    Reuss, A.
    DuBois, A.
    Kommoss, S.
    Kommoss, F.
    Gao, D.
    Kalloger, S. E.
    Huntsman, D. G.
    Gilks, C. B.
    MODERN PATHOLOGY, 2010, 23 : 250A - 250A
  • [4] Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
    Kasherman, Lawrence
    Garg, Swati
    Tchrakian, Nairi
    Clarke, Blaise
    Karakasis, Katherine
    Kim, Raymond H.
    Stockley, Tracy L.
    Dhani, Neesha
    Oza, Amit M.
    Lheureux, Stephanie
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 36
  • [5] High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07)
  • [6] Type of TP53 alteration may correlate with the extent of lymphocytic infiltration in high-grade serous ovarian carcinomas
    Sokolenko, A.
    Ivantsov, A.
    Bizin, I.
    Gorodnova, T.
    Kotiv, K.
    Imyanitov, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1459 - S1459
  • [7] TP53-wildtype High-Grade Serous Tubo-Ovarian Carcinomas
    Chui, M. Herman
    Soslow, Robert
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1029 - 1029
  • [8] TP53-wildtype High-Grade Serous Tubo-Ovarian Carcinomas
    Chui, M. Herman
    Soslow, Robert
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1029 - 1029
  • [9] Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
    Tuna, Musaffe
    Ju, Zhenlin
    Yoshihara, Kosuke
    Amos, Christopher I.
    Tanyi, Janos L.
    Mills, Gordon B.
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 405 - 412
  • [10] TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?
    Oien, Derek B.
    Chien, Jeremy
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S264 - S268
12345